Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The plant is a dedicated for manufacturing of Mouth dissolving strip.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The company is now introducing the product into the India pharmaceutical market.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The production suspension impacts commercial and clinical trial supply
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Subscribe To Our Newsletter & Stay Updated
